Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13868
UPID:
EXOS2_HUMAN
Alternative names:
Exosome component 2; Ribosomal RNA-processing protein 4
Alternative UPACC:
Q13868; A3KFL3; A3KFL4; B4DKK6; Q9NUY4
Background:
Exosome complex component RRP4, also known as Exosome component 2 and Ribosomal RNA-processing protein 4, plays a crucial role in RNA metabolism. It is a non-catalytic component of the RNA exosome complex, involved in the degradation and processing of RNA molecules. This protein ensures the proper maturation of stable RNA species and the elimination of defective mRNAs, contributing to cellular homeostasis.
Therapeutic significance:
The involvement of Exosome complex component RRP4 in the disorder characterized by short stature, hearing loss, retinitis pigmentosa, and distinctive facies highlights its potential as a therapeutic target. Understanding the role of Exosome complex component RRP4 could open doors to potential therapeutic strategies for this autosomal recessive disorder.